Opsite IV 3000 60mm x 85mm 1 Cura Pharm is a specialized negative pressure wound therapy system designed for controlled exudate management and optimal wound healing. This configuration is commonly selected for smaller or moderately sized wounds where a cohesive, medicated interface is clinically indicated.
The integration of 1 Cura Pharm foam provides a defined cushioning effect and combines advanced absorption with a pharmaceutical-grade interface to support a reliable and predictable treatment course. Below is a detailed overview of its technical profile, clinical considerations, and practical handling guidance.
Product Identification And Coding
Proper identification of Opsite IV 3000 60mm x 85mm 1 Cura Pharm is essential for inventory control, clinical documentation, and regulatory compliance. Each unit carries unique codes that link the device platform to the specific foam interface, ensuring traceability from the supply chain to the point of care.
Key Markings And Components
The labeling, packaging, and integrated components communicate critical information for clinicians. The structured format below captures the most relevant identifiers and their intended use in routine practice.
| Attribute | Specification | Clinical Relevance | Example Reference |
|---|---|---|---|
| Device Platform | Opsite IV 3000 | Indicates the primary negative pressure interface and pump compatibility | Opsite IV 3000 |
| Foam Dimensions | 60mm x 85mm | Defines the coverage area and suitability for localized wounds | 60mm x 85mm |
| Cura Interface | 1 Cura Pharm | Denotes a pharmaceutically optimized foam layer for controlled interaction with wound bed | 1 Cura Pharm |
| Sterility Status | Single-use, sterile | Ensures safety and compatibility with acute and select chronic wound protocols | Sterile, single-use |
| Intended Use | Management of exuding wounds | Supports a moist environment while managing excess fluid | Exudate management |
Clinical Application And Positioning
Opsite IV 3000 3000 60mm x 85mm 1 Cura Pharm is positioned within advanced wound care where reliable exudate control, protection, and interface comfort are prioritized. The foam configuration is selected based on wound size, depth, and the presence of peri-wound fragile skin.
When used as part of a structured wound management plan, this dressing aligns therapy goals with measurable outcomes. Clinicians evaluate tissue response, maceration risk, and patient adherence to refine selection over time.
Handling, Storage, And Safety Considerations
Appropriate handling and storage practices are essential to preserve the integrity of Opsite IV 3000 60mm x 85mm 1 Cura Pharm from the point of receipt to application. Following manufacturer guidance minimizes contamination risk and optimizes device performance.
- Store in a cool, dry environment within the recommended temperature range specified on the packaging.
- Inspect the sterile pouch for any breaches or damage before opening and using the product.
- Maintain aseptic technique throughout preparation and application to the wound bed.
- Document lot number and expiry date in patient records to support traceability and safety monitoring.
Integration Into Wound Care Protocols
Integration of Opsite IV 3000 60mm x 85mm 1 Cura Pharm into clinical pathways requires coordination among multidisciplinary teams, including wound care specialists, nursing staff, and prescribing clinicians. Success depends on consistent assessment, timely dressing changes, and aligned therapeutic objectives.
Device compatibility with negative pressure pumps should be verified, and any adjunctive therapies or topical agents should be reviewed for interaction with the Cura Pharm interface. Establishing clear monitoring parameters helps determine suitability and continuation of this specific configuration.
Operational Guidance And Best Practice Recommendations
To optimize the use of Opsite IV 3000 60mm x 85mm 1 Cura Pharm within everyday practice, teams should align handling, documentation, and monitoring procedures. The following points highlight actionable steps to support safe and effective implementation.
- Verify patient-specific suitability through wound assessment and clinical judgment before selection.
- Confirm compatibility with institutional equipment and policies, including negative pressure systems.
- Adhere to storage conditions and sterility protocols to maintain device integrity.
- Record detailed application notes, including lot number, orientation, and observed tissue response at each change.
FAQ
Reader questions
Is this dressing suitable for infected wounds?
Yes, Opsite IV 3000 60mm x 85mm 1 Cura Pharm can be used in conjunction with standard antimicrobial therapies when clinically indicated, subject to clinician assessment and local policy. The sealed system supports a controlled environment while managing exudate.
How often should the dressing be changed?
Frequency depends on exudate levels, wound characteristics, and clinical protocol, typically ranging from every few days to several days. Clinicians should reassess at each review and change based on saturation and tissue response.
Can this be used on neuropathic ulcers?
It is suitable for selected neuropathic ulcers when exudate management and offloading considerations are addressed. A thorough vascular and neurological assessment, along with device compatibility with the wound base, should guide use in these cases.
Does the 1 Cura Pharm interface require special training to apply?
Application follows standard negative pressure wound therapy principles with attention to foam positioning, seal integrity, and pump settings. Facilities may provide targeted training to ensure consistent and safe use by clinicians.